defined a four-gene IFNγ positive (IFNγ+) signature comprising IFNγ, CD274, LAG3, and CXCL9 through RNA sequencing of biopsies from advanced-stage NSCLC treated with durvalumab. The gene discussed is CD274; the disease is non-small cell lung carcinoma.